Skip to main content
Premium Trial:

Request an Annual Quote

Frank Chisari, Jules Dienstag, Thomas London, John McHutchison, Robert Perrillo, and Robert Desimone

Premium

Nucleonics recently named the members of its clinical advisory board, including Frank Chisari; Jules Dienstag; Thomas London; John McHutchison; and Robert Perrillo.

Chisari is professor of virology and head of the division of experimental pathology at the Scripps Research Institute. According to Nucleonics, his work extends into the fields of hepatitis B and C, as well as cancer. Recently, Chisari and his colleagues used RNAi to suppress replication of hepatitis in cell culture and animal models, the company said.

Nucleonics has an existing collaboration with Chisari on the development of hepatitis B and C drug candidates.

Dienstag is associate professor of medicine at Harvard Medical School, and is executive director of the liver, biliary, and pancreas center at Massachusetts General Hospital. Dienstag has focused his career on researching viral hepatitis, Nucleonics said.

London is the director of the Liver Cancer Prevention Center, and is a senior member of the Fox Chase Cancer Center. In 1998, he received the distinguished scientist award from the Hepatitis B Foundation, said Nucleonics.

McHutchison is medical director of gastroenterology and hepatology research at Duke University’s Duke Clinical Research Institute. Nucleonics said he has published widely on the topic of liver diseases, particularly hepatitis C, and has been involved with the development of numerous hepatitis C drug candidates.

Perrillo is the director of academic affairs for the section of gastroenterology and hepatology at the Ochsner Clinic Foundation. According to Nucleonics, he has been a clinical investigator in the areas of alpha interferon treatment of chronic hepatitis, and has been a contributor to the medical literature on the use of nucleoside analogue therapy in patients with advanced hepatitis B.


The McGovern Institute at MIT said last week that it has selected Robert Desimone, scientific director of the intermural research program of the National Institutes of Mental Health, as its next director.

Desimone will be replacing the current director Phillip Sharp.

Desimone holds a BA from Macalester College and a PhD from Princeton University.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.